9/10/2026
Rhelion Life Sciences launches stability program for ibogaine
Filament Health begins stability testing for IBEX011, a botanical ibogaine drug.
Topic archive
45 stories
9/10/2026
Filament Health begins stability testing for IBEX011, a botanical ibogaine drug.
9/10/2026
Filament Health begins stability program for IBEX011 amid rising ibogaine demand.
9/10/2026
The FDA highlights its evolving approach to psychedelic therapies amid a mental health crisis.
9/10/2026
IBEX011 stability program aims to meet growing demand for standardized ibogaine.
9/3/2026
Veterans push for ibogaine to treat PTSD and addiction.
9/1/2026
The study aims to explore ibogaine's potential for treating PTSD and addiction.
8/26/2026
Ibogaine shows promise for PTSD, but remains illegal in the U.S.
8/26/2026
The move promotes open science and could influence future psychedelic research.
8/21/2026
The move could expedite psychedelic research for veteran treatment.
8/21/2026
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
8/21/2026
David Dardashti shares clinical footage as psychedelic therapy gains federal interest.
8/21/2026
Trump administration accelerates psychedelic research for veterans' mental health.
8/19/2026
Barrow Neurological Institute to test ibogaine's safety and efficacy in a state-funded trial.
8/19/2026
Trump's administration advances psychedelic therapies for PTSD and TBI in veterans.
8/19/2026
Market optimism grows as Psyence Biomedical advances ibogaine studies.
8/19/2026
Former President Trump supports ibogaine research, sparking industry response.
8/19/2026
Company aligns with U.S. efforts to advance ibogaine research.
8/19/2026
Trump announces transfer of ibogaine investigational drug application to accelerate research.
8/19/2026
Barrow Neurological Institute to explore ibogaine's potential for PTSD and brain injuries.
8/16/2026
Research highlights ibogaine's potential in opioid addiction and multiple sclerosis.
8/15/2026
David Dardashti advocates ibogaine as a medical solution for kratom dependency.
8/12/2026
NBC 7 San Diego video delves into ibogaine's impact on the brain.
8/8/2026
AtaiBeckley and Compass Pathways explore new opportunities.
8/7/2026
Rick Perry and Bryan Hubbard lead efforts to legitimize ibogaine in Texas.
8/7/2026
Ibogaine's potential in treating PTSD and opioid addiction in veterans examined.
8/6/2026
Police probe follows death linked to unauthorized ibogaine use in Canada.
8/6/2026
The trial will explore ibogaine's potential in treating chronic TBI symptoms.
8/5/2026
Thirty years of ibogaine studies reveal potential but highlight risks.
8/5/2026
Police charge Mississauga man after ibogaine-related death, highlighting risks.
8/5/2026
Jonathan Dickinson discusses ibogaine's potential in treating PTSD and brain injuries.
7/31/2026
Luttrell's IBOGAINE Act aims to solidify psychedelic therapy access for veterans.
7/29/2026
Psychedelic trials often exclude marginalized groups, raising questions about equity and efficacy.
7/29/2026
Ibogaine HCl aims to treat PTSD, TBI, and opioid use disorder.
7/29/2026
State-led ibogaine study in Texas gains federal backing, marking a significant research development.
7/28/2026
YouTube video explores ibogaine's potential in treating disorders.
7/24/2026
White House adviser Heidi Overton shapes ibogaine policy amid internal disputes.
7/24/2026
Psychoactive drug ibogaine gains attention for addiction treatment potential.
7/24/2026
The Tijuana-based center marks a milestone in ibogaine treatment for substance use disorder.
7/24/2026
The Trump administration considers making ibogaine available for therapeutic use.
7/23/2026
The amendment aims to expand treatment options for PTSD and addiction.
7/22/2026
Proposed NDAA amendment aims to expand treatment options for PTSD and TBI.
7/21/2026
Stanford Veterans Study highlights ibogaine's potential for PTSD treatment.
7/16/2026
Veterans report transformative effects from psychedelic therapy.
7/16/2026
Veterans share recovery stories, highlighting ibogaine's potential.
7/15/2026
Federal support for ibogaine and other psychedelics aims to aid veterans with PTSD.